By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

Continued maintenance BCG might be considered in BCG-responsive patients with very high-risk NMIBC without adverse clinical and pathologic features. Rather than undergo upfront radical cystectomy, ...

The bacillus Calmette-Guérin (BCG) vaccine nearly halved the risk of progression among patients with non–muscle invasive bladder cancer (NMIBC) compared with transurethral resection of the bladder ...

SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to ...

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...

Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study. The University of Chicago Medicine received approval from the ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high ...